Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Medically reviewed by Brendan Camp, MD Psoriasis affects about 3% of all adults in the United States, and Asian Americans ...

Dr. Carolyn Stull, board-certified dermatologist of MDCS Dermatology in New York City, described psoriasis as a chronic ...

You can apply sunscreen to psoriasis plaques to prevent sunburn, but, if the plaques from psoriasis are inflamed or cracked ...

The study is published in Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease. Psoriasis is a hereditary, chronic ...

Navigating a chronic skin condition can impact daily life and relationship dynamics. Real couples and a doctor dive deeper on ...

People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased ...

A recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208 weeks (approximately 4 years). This ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Discover the hidden inflammation in psoriasis patients' intestines, its link to leaky gut, and the increased risk of Crohn's ...